Project Grant R01AI186964
Award Date
12/23/24
Completion Date
11/30/29
Dollars Obligated
$318K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Not listed
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Cardiff, UK
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), provides $416,276 to the University of Georgia Research Foundation, Inc. to conduct research aimed at increasing the protective capacity of antibodies by enhancing Fc-mediated immune responses. The key objectives are to: 1) quantify how factors such as epitope location, antibody glycosylation, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $848,839 to the University of Massachusetts Medical School (UMass Medical) to investigate new mechanisms by which HIV accessory proteins mediate control of natural killer (NK) cell function. The key objectives are to identify novel HIV-regulated NK cell ligands, define how the HIV Vif protein regulates MHC-I...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to North Carolina State University for $470,989, with a project period from December 2024 to November 2029. The grant aims to systematically identify functional single nucleotide polymorphisms (SNPs) in the Fc gamma receptor (FcR) locus and determine their impact on antibody-mediated functions such as antibody-dependent cellular...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to characterize HIV reservoirs in macrophages and investigate mechanisms by which these cells resist antibody-dependent cellular cytotoxicity (ADCC). The $243,713 award to the University of Massachusetts Medical School aims to: 1) determine how HIV accessory proteins Nef and Vpu differentially regulate NK cell...
This Project Grant award of $666,567 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the University of California, Los Angeles (UCLA) to investigate the transcriptional regulation of human natural killer (NK) cell function in response to viral infections, such as human cytomegalovirus (HCMV). The key objectives are to determine the mechanisms by which the transcription factor MEF2C regulates NK cell...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,620 to Albert Einstein College of Medicine to develop broadly protective human monoclonal antibody therapies against alphaviruses. The key goals are to: 1) engineer Fc mutations to enhance the in vitro and in vivo properties of broadly neutralizing antibodies, 2) perform viral escape studies to define mechanisms...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $142,908 to the San Diego Biomedical Research Institute to conduct research on how antibody glycosylation influences natural killer (NK) cell activation and antibody-dependent cellular cytotoxicity (ADCC) during HIV infection. The key objectives are to: 1) Determine how monoclonal antibody glycosylation profiles affect signaling protein...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $303,076 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Washington. The grant, awarded on November 5, 2024, supports research to understand how viruses evade and co-opt the body's innate immune defenses, specifically focusing on how enteric viruses develop resistance to antimicrobial peptides called defensins. The research aims to elucidate the molecular,...
The federal Project Grant award R01AI192874 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $649,530 award supports research to understand how B cells and their antibody receptors can contribute to protection from or susceptibility to dengue virus infection and disease progression. The project aims to define the mechanistic requirements underpinning B cell receptor-dependent...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $525,095 to the University of Rochester to conduct research on cellular determinants of human cytomegalovirus (HCMV) infection. The research aims to identify mechanisms through which the cellular factor JUNB can restrict HCMV infection and how the viral protein UL26 modulates JUNB's activity, with the goal of...